Trials / Withdrawn
WithdrawnNCT03374670
ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
A Phase 2A Open-Label Trial to Assess the Safety of ZIMURA™ (Anti-C5) in Combination With EYLEA® in Treatment Experienced Subjects With Idiopathic Polypoidal Choroidal Vasculopathy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Ophthotech Corporation · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zimura | Zimura in combination with Eylea |
| DRUG | Eylea | Zimura in combination with Eylea |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2017-12-15
- Last updated
- 2024-02-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03374670. Inclusion in this directory is not an endorsement.